Physician profile
Anna Fleisher
NPI 1720563638
$2,545.02
in general payments reported to CMS, 2019-2025
10 companies · $951 in 2025
The $951 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.38 · 2023: $577 · 2024: $936 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,008.89 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $584.28 | 2023-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.21 | 2023-2025 | Xifaxan, Trulance |
| Viiv Healthcare Company | $317.81 | 2023-2025 | Apretude |
| Lilly USA, LLC | $175.33 | 2022-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $36.22 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $26.73 | 2024 | Repatha |
| Agile Therapeutics, INC. | $23.16 | 2022 | |
| Ionis Pharmaceuticals, INC. | $22.76 | 2025 | Tryngolza |
| Abbvie INC. | $18.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Fleisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.